Get access

Selective vasopressin type 2 receptor antagonist for patients with cirrhosis

  • Protocol
  • Intervention

Authors

  • Norberto C Chavez-Tapia,

    Corresponding author
    1. Medica Sur Clinic & Foundation, Obesity and Digestive Diseases Unit, Mexico City, Mexico
    • Norberto C Chavez-Tapia, Obesity and Digestive Diseases Unit, Medica Sur Clinic & Foundation, Puente de Piedra 150, Mexico City, 14050, Mexico. khavez@gmail.com.

    Search for more papers by this author
  • Tonatiuh Barrientos-Gutierrez,

    1. National Institute of Public Health, Tobacco Research Department, Mexico City, Mexico City, Mexico
    Search for more papers by this author
  • Felix I Tellez-Avila,

    1. Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Department of Gastroenterology, Mexico City, Distrito Federal, Mexico
    Search for more papers by this author
  • Nahum Mendez-Sanchez,

    1. Medica Sur Clinic & Foundation, Dept. of Biomedical Research, Gastroenterology & Liver Unit, Tlalpan, Mexico City, Mexico
    Search for more papers by this author
  • Misael Uribe

    1. Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Department of Gastroenterology, Mexico City, Distrito Federal, Mexico
    Search for more papers by this author

Abstract

This is the protocol for a review and there is no abstract. The objectives are as follows:

To assess the benefits and harms of selective vasopressin type 2 receptor antagonist drugs for patients with cirrhosis and ascites.

Ancillary